Direct oral anticoagulants combined with antiplatelet in the treatment of acute coronary syndrome and atrial fibrillation patients undergoing percutaneous coronary intervention or complicating acute coronary syndrome: a systematic review and meta-ana

The combination of DOACs and APT requires a tailored approach. For ACS patients, therapy should center on balancing ischemic and bleeding risks, favoring those at high ischemic risk but low or manageable bleeding risk. In contrast, for AF patients undergoing PCI or complicating ACS, the regimen is aimed at risk minimization and is most suitable for patients in whom this is the primary concern.<b>Protocol registration:</b> www.crd.york.ac.uk/prospero identifier is CRD42025645639.

Authors

Institutions

Publication Details

Journal
Expert Opinion on Drug Safety
Published
2025-12-31
DOI
https://doi.org/10.1080/14740338.2025.2596236
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Direct oral anticoagulants combined with antiplatelet in the treatment of acute coronary syndrome and atrial fibrillation patients undergoing percutaneous coronary intervention or complicating acute coronary syndrome: a systematic review and meta-ana

B. Zhang, Delong Liu, Guojun Zhao, Shuyun Lin et al.
Expert Opinion on Drug Safety
Atrial Fibrillation Management and Outcomes
article

Direct oral anticoagulants combined with antiplatelet in the treatment of acute coronary syndrome and atrial fibrillation patients undergoing percutaneous coronary intervention or complicating acute coronary syndrome: a systematic review and meta-ana

B. Zhang, Delong Liu, Guojun Zhao, Shuyun Lin, Lili Liu, Lexie Bai
article en

Abstract

The combination of DOACs and APT requires a tailored approach. For ACS patients, therapy should center on balancing ischemic and bleeding risks, favoring those at high ischemic risk but low or manageable bleeding risk. In contrast, for AF patients undergoing PCI or complicating ACS, the regimen is aimed at risk minimization and is most suitable for patients in whom this is the primary concern.<b>Protocol registration:</b> www.crd.york.ac.uk/prospero identifier is CRD42025645639.

Expert Opinion on Drug SafetyVol. 25(3)
Dali University (CN), Guangzhou Medical University (CN)
Good health and well-being
Openalex Percentile: Top 30%
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.